Regeneron Pharmaceuticals
REGN
414 hedge funds and large institutions have $24B invested in Regeneron Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 79 funds opening new positions, 169 increasing their positions, 124 reducing their positions, and 34 closing their positions.
132% more first-time investments, than exits
New positions opened: 79 | Existing positions closed: 34
44% more funds holding in top 10
Funds holding in top 10: 9 → 13 (+4)
41% more capital invested
Capital invested by funds: $17B → $24B (+$7.04B)
36% more repeat investments, than reductions
Existing positions increased: 169 | Existing positions reduced: 124
12% more funds holding
Funds holding: 371 → 414 (+43)
3% less call options, than puts
Call options by funds: $388M | Put options by funds: $401M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$182M |
| 2 |
Sands Capital Management
Arlington,
Virginia
|
+$168M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$142M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$94.5M |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$354M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$153M |
| 3 |
JP Morgan Chase
New York
|
-$87.3M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$86.8M |
| 5 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$63.4M |
REGN Hedge Fund Activity: Q3 2013 in Review
414 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q3 2013, worth a combined $24B — up 41% from $17B a quarter earlier.
Buyers outnumbered sellers: 79 funds opened new REGN positions and 34 closed out — a net gain of 45 holders — while 169 added to existing stakes and 124 trimmed.
The largest buyer was Deutsche Bank, adding an estimated $182M. The largest seller was Fidelity Investments, cutting an estimated $354M.
- 414 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q3 2013, up from 371 in Q2 2013.
- Funds reported $24B of Regeneron Pharmaceuticals stock for Q3 2013, up 41% quarter-over-quarter.
- 79 funds opened new Regeneron Pharmaceuticals positions in Q3 2013 and 34 closed out, a net change of +45 holders.
- The largest Regeneron Pharmaceuticals buyer in Q3 2013 was Deutsche Bank, an estimated $182M added.
- The largest Regeneron Pharmaceuticals seller in Q3 2013 was Fidelity Investments, an estimated $354M sold.
Based on aggregated 13F filings for Q3 2013.